Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

DQueST: dynamic questionnaire for search of clinical trials.

Liu C, Yuan C, Butler AM, Carvajal RD, Li ZR, Ta CN, Weng C.

J Am Med Inform Assoc. 2019 Aug 7. pii: ocz121. doi: 10.1093/jamia/ocz121. [Epub ahead of print]

PMID:
31390010
2.

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M.

JAMA Oncol. 2019 Jul 25. doi: 10.1001/jamaoncol.2019.2187. [Epub ahead of print]

3.

Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.

Damato BE, Dukes J, Goodall H, Carvajal RD.

Cancers (Basel). 2019 Jul 11;11(7). pii: E971. doi: 10.3390/cancers11070971. Review.

4.

Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan.

Francis JH, Barker CA, Yin VT, Carvajal RD, Chapman P, Abramson DH, Gobin YP.

Ocul Oncol Pathol. 2019 Apr;5(3):186-189. doi: 10.1159/000490061. Epub 2018 Oct 9.

PMID:
31049326
5.

Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.

Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK.

Cancer Res. 2019 May 1;79(9):2415-2425. doi: 10.1158/0008-5472.CAN-18-3177. Epub 2019 Mar 18.

PMID:
30885979
6.

KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.

Meng D, Carvajal RD.

Am J Clin Dermatol. 2019 Jun;20(3):315-323. doi: 10.1007/s40257-018-0414-1.

PMID:
30707374
7.

Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference.

Smith JR, Pe'er J, Belfort RN, Cardoso F, Carvajal RD, Carvalho C, Coupland SE, Desjardins L, Francis JH, Gallie BL, Gombos DS, Grossniklaus HE, Heegaard S, Jager MJ, Kaliki S, Ksander BR, Maeurer M, Moreno E, Pulido JS, Ryll B, Singh AD, Zhao J, Parreira A, Wilson DJ, O'Brien JM.

Transl Vis Sci Technol. 2018 Jan 9;8(1):9. doi: 10.1167/tvst.8.1.9. eCollection 2019 Jan.

8.

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.

Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE.

EMBO Mol Med. 2019 Feb;11(2). pii: e9081. doi: 10.15252/emmm.201809081.

9.

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.

Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P.

J Immunother Cancer. 2018 Sep 25;6(1):93. doi: 10.1186/s40425-018-0407-x.

10.

Prognostic Value of Low Tumor Burden in Patients With Melanoma.

Poklepovic AS, Carvajal RD.

Oncology (Williston Park). 2018 Sep 15;32(9):e90-e96. Review.

11.

A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.

D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Hensley ML, Hirst CM, Ezeoke MO, Ahn L, Qin LX, Antonescu CR, Lefkowitz RA, Maki RG, Schwartz GK, Tap WD.

Oncologist. 2019 Jun;24(6):857-863. doi: 10.1634/theoncologist.2018-0160. Epub 2018 Aug 20.

PMID:
30126857
12.

Secondary Prevention Strategies for Nonmelanoma Skin Cancer.

Lopez AT, Carvajal RD, Geskin L.

Oncology (Williston Park). 2018 Apr 15;32(4):195-200. Review.

13.

The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.

Yang J, Hamid O, Carvajal RD.

Clin Cancer Res. 2018 Aug 1;24(15):3477-3479. doi: 10.1158/1078-0432.CCR-18-0020. Epub 2018 Apr 2.

14.

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P.

J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. Erratum in: J Clin Oncol. 2018 Dec 10;36(35):3528.

PMID:
29528792
15.

Treatment of uveal melanoma: where are we now?

Yang J, Manson DK, Marr BP, Carvajal RD.

Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175. doi: 10.1177/1758834018757175. eCollection 2018. Review.

16.

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA.

Clin Cancer Res. 2018 Apr 15;24(8):1881-1890. doi: 10.1158/1078-0432.CCR-17-3103. Epub 2018 Jan 23.

17.

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.

Chung DJ, Carvajal RD, Postow MA, Sharma S, Pronschinske KB, Shyer JA, Singh-Kandah S, Dickson MA, D'Angelo SP, Wolchok JD, Young JW.

Oncoimmunology. 2017 Sep 21;7(1):e1372081. doi: 10.1080/2162402X.2017.1372081. eCollection 2017.

18.

JAK-ing up the Response to KIT Inhibition.

Yang J, Komatsubara KM, Carvajal RD.

J Invest Dermatol. 2018 Jan;138(1):6-8. doi: 10.1016/j.jid.2017.09.003.

19.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

20.

Mucosal Melanoma: New Insights and Therapeutic Options for a Unique and Aggressive Disease.

Lerner BA, Stewart LA, Horowitz DP, Carvajal RD.

Oncology (Williston Park). 2017 Nov 15;31(11):e23-e32. Review.

21.

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

D'Angelo SP, Hamid OA, Tarhini A, Schadendorf D, Chmielowski B, Collichio FA, Pavlick AC, Lewis KD, Weil SC, Heyburn J, Schweizer C, O'Shannessy DJ, Carvajal RD.

Invest New Drugs. 2018 Feb;36(1):103-113. doi: 10.1007/s10637-017-0530-4. Epub 2017 Nov 11.

PMID:
29127533
22.

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.

Hamid O, Hoffner B, Gasal E, Hong J, Carvajal RD.

Cancer Immunol Immunother. 2017 Oct;66(10):1249-1264. doi: 10.1007/s00262-017-2025-8. Epub 2017 Jul 15. Review.

23.

Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.

Komatsubara KM, Jeter J, Carvajal RD, Margolin K, Schadendorf D, Hauschild A.

Am Soc Clin Oncol Educ Book. 2017;37:641-650. doi: 10.14694/EDBK_175265. Review.

PMID:
28561682
24.

Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Komatsubara KM, Carvajal RD.

Curr Oncol Rep. 2017 Jul;19(7):45. doi: 10.1007/s11912-017-0606-5. Review.

PMID:
28508938
25.

Adopting a new stance on immunotherapy for uveal melanoma.

Komatsubara KM, Carvajal RD.

Lancet Oncol. 2017 Jun;18(6):702-704. doi: 10.1016/S1470-2045(17)30254-1. Epub 2017 Apr 7. No abstract available.

PMID:
28395881
26.

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.

Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS.

Ann Oncol. 2017 Jun 1;28(6):1380-1387. doi: 10.1093/annonc/mdx079.

27.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF.

Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.

28.

Patient perspectives on ipilimumab across the melanoma treatment trajectory.

Shuk E, Shoushtari AN, Luke J, Postow MA, Callahan M, Harding JJ, Roth KG, Flavin M, Granobles A, Christian J, Gold G, Schoenhammer M, Gordon M, Cimaglia N, Dyson R, Goodman-Davis N, Colgan MN, Jefferson IS, Munhoz R, D'Angelo S, Wolchok J, Chapman P, Chi P, Carvajal RD, Hay JL.

Support Care Cancer. 2017 Jul;25(7):2155-2167. doi: 10.1007/s00520-017-3621-z. Epub 2017 Mar 1.

29.

Uveal melanoma: epidemiology, etiology, and treatment of primary disease.

Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD.

Clin Ophthalmol. 2017 Jan 31;11:279-289. doi: 10.2147/OPTH.S89591. eCollection 2017. Review.

30.

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.

D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth MJ, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu C, DeMatteo RP, Carvajal RD, Tap WD.

Clin Cancer Res. 2017 Jun 15;23(12):2972-2980. doi: 10.1158/1078-0432.CCR-16-2349. Epub 2016 Dec 22.

31.

Update on the treatment of uveal melanoma.

Carvajal RD.

Clin Adv Hematol Oncol. 2016 Oct;14(10):768-770. No abstract available.

PMID:
27930627
32.

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.

Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD.

J Cancer Res Clin Oncol. 2017 Mar;143(3):439-445. doi: 10.1007/s00432-016-2318-x. Epub 2016 Dec 5.

33.

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, Munhoz RR, Buchar G, Hester RH, Romero JA, Fitzpatrick LJ, Weiser MR, Panageas KS, Wolchok JD, Chapman PB, Carvajal RD.

Melanoma Res. 2017 Feb;27(1):57-64. doi: 10.1097/CMR.0000000000000306.

34.

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ.

Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.

35.

The promise and pitfalls of the many methods of plasma genotyping.

Komatsubara KM, Carvajal RD, Sacher AG.

Expert Opin Biol Ther. 2016 Nov;16(11):1313-1316. Epub 2016 Sep 12. No abstract available.

PMID:
27608417
36.

Metastatic disease from uveal melanoma: treatment options and future prospects.

Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD.

Br J Ophthalmol. 2017 Jan;101(1):38-44. doi: 10.1136/bjophthalmol-2016-309034. Epub 2016 Aug 29. Review.

37.

Melanoma driver mutations and immune therapy.

Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA.

Oncoimmunology. 2016 Mar 10;5(5):e1051299. doi: 10.1080/2162402X.2015.1051299. eCollection 2016 May.

38.

Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract.

Schiavone MB, Broach V, Shoushtari AN, Carvajal RD, Alektiar K, Kollmeier MA, Abu-Rustum NR, Leitao MM Jr.

Gynecol Oncol Rep. 2016 Apr 14;16:42-6. doi: 10.1016/j.gore.2016.04.001. eCollection 2016 Apr.

39.

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.

Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, Postow MA.

Oncologist. 2016 Jul;21(7):848-54. doi: 10.1634/theoncologist.2015-0522. Epub 2016 Jun 10.

40.

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.

Beck KM, Dong J, Geskin LJ, Beltrani VP, Phelps RG, Carvajal RD, Schwartz G, Saenger YM, Gartrell RD.

J Immunother Cancer. 2016 Apr 19;4:20. doi: 10.1186/s40425-016-0123-3. eCollection 2016.

41.

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.

Gulati N, Carvajal RD, Postow MA, Wolchok JD, Krueger JG.

Exp Dermatol. 2016 Jul;25(7):553-4. doi: 10.1111/exd.13030. No abstract available.

42.

Programmed death 1 immune checkpoint inhibitors.

Trivedi MS, Hoffner B, Winkelmann JL, Abbott ME, Hamid O, Carvajal RD.

Clin Adv Hematol Oncol. 2015 Dec;13(12):858-68. Review.

PMID:
27058852
43.

Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.

Komatsubara KM, Manson DK, Carvajal RD.

Future Oncol. 2016 Jun;12(11):1331-44. doi: 10.2217/fon-2015-0075. Epub 2016 Apr 5. Review.

PMID:
27044592
44.

Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.

Samstein RM, Carvajal RD, Postow MA, Callahan MK, Shoushtari AN, Patel SG, Lee NY, Barker CA.

Head Neck. 2016 Sep;38(9):1310-7. doi: 10.1002/hed.24435. Epub 2016 Apr 4.

45.

Clinical utility of nivolumab in the treatment of advanced melanoma.

Asmar R, Yang J, Carvajal RD.

Ther Clin Risk Manag. 2016 Feb 26;12:313-25. doi: 10.2147/TCRM.S78039. eCollection 2016. Review.

46.

The promise and challenges of rare cancer research.

Komatsubara KM, Carvajal RD.

Lancet Oncol. 2016 Feb;17(2):136-138. doi: 10.1016/S1470-2045(15)00485-4. No abstract available.

PMID:
26868336
47.

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.

Shoushtari AN, Ong LT, Schoder H, Singh-Kandah S, Abbate KT, Postow MA, Callahan MK, Wolchok J, Chapman PB, Panageas KS, Schwartz GK, Carvajal RD.

Melanoma Res. 2016 Jun;26(3):272-7. doi: 10.1097/CMR.0000000000000234.

48.

Clinical Management of Uveal and Conjunctival Melanoma.

Blum ES, Yang J, Komatsubara KM, Carvajal RD.

Oncology (Williston Park). 2016 Jan;30(1):29-32, 34-43, 48. Review.

49.

Reply to A. Indini et al.

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB.

J Clin Oncol. 2016 Mar 20;34(9):1018-9. doi: 10.1200/JCO.2015.65.7007. Epub 2016 Jan 19. No abstract available.

PMID:
26786917
50.

Evaluating Chemotherapy at the End of Life.

Provenzano AF, Carvajal RD.

JAMA Oncol. 2016 Jan;2(1):142-3. doi: 10.1001/jamaoncol.2015.4105. No abstract available.

PMID:
26767555

Supplemental Content

Loading ...
Support Center